Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol.

A series of benzo-macrolactones of varying ring size and conformation has been prepared by chemical synthesis and evaluated by structural and biological techniques. Thus, 12- to 16-membered lactones were obtained by concise routes, involving ring-closing metathesis as a key step. In enzyme assays, the 13-, 15-, and 16-membered analogs are good inhibitors, suggesting that they can adopt the required conformation to fit in the ATP-binding site. This was confirmed by cocrystallization of 13-, 14-, and 15-membered lactones with the N-terminal domain of yeast Hsp90, showing that they bind similarly to the "natural" 14-membered radicicol. The most active compounds in the ATPase assays also showed the greatest growth-inhibitory potency in HCT116 human colon cancer cells and the established molecular signature of Hsp90 inhibition, i.e., depletion of client proteins with upregulation of Hsp70.

[1]  S. Lakhani,et al.  Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  X. Barril,et al.  A fluorescence polarization assay for inhibitors of Hsp90. , 2006, Analytical biochemistry.

[3]  S. Faeth,et al.  Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert. , 2006, Journal of natural products.

[4]  Xiao Ming Yu,et al.  Hsp90 inhibitors identified from a library of novobiocin analogues. , 2005, Journal of the American Chemical Society.

[5]  P. Workman,et al.  HSP90 as a new therapeutic target for cancer therapy: the story unfolds , 2002, Expert opinion on biological therapy.

[6]  S. Barluenga,et al.  Solution- and solid-phase synthesis of radicicol (monorden) and pochonin C. , 2005, Chemistry.

[7]  N. Rosen,et al.  Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. , 2004, Chemistry & biology.

[8]  P. Workman,et al.  Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo. , 2000, Molecular pharmacology.

[9]  Scott A Lesley,et al.  Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. , 2005, Bioorganic & medicinal chemistry letters.

[10]  D. Mok,et al.  Modulation of Chaperone Function and Cochaperone Interaction by Novobiocin in the C-terminal Domain of Hsp90 , 2006, Journal of Biological Chemistry.

[11]  L. Pearl,et al.  Structure and mechanism of the Hsp90 molecular chaperone machinery. , 2006, Annual review of biochemistry.

[12]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: current status. , 2006, Advances in cancer research.

[13]  J. Caldwell,et al.  Crystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles , 2005 .

[14]  Xavier Barril,et al.  Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.

[15]  B. Blagg,et al.  Hsp90 inhibitors: Small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation , 2006, Medicinal research reviews.

[16]  N. Rosen,et al.  Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol. , 2003, Angewandte Chemie.

[17]  L. Pearl,et al.  Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. , 1999, Journal of medicinal chemistry.

[18]  S. Akinaga,et al.  Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. , 2002, Bioorganic & medicinal chemistry.

[19]  Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. , 2004, Organic letters.

[20]  L. Pearl,et al.  Expression and crystallization of the yeast Hsp82 chaperone, and preliminary x‐ray diffraction studies of the amino‐terminal domain , 1996, Proteins.

[21]  P. Delmotte,et al.  A New Antifungal Substance of Fungal Origin , 1953, Nature.

[22]  C. Pratilas,et al.  New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target. , 2004, Journal of the American Chemical Society.

[23]  Gabriela Chiosis,et al.  Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. , 2005, Journal of medicinal chemistry.

[24]  B. Blagg,et al.  Radester, a novel inhibitor of the Hsp90 protein folding machinery. , 2005, Organic letters.

[26]  C. W. Shoppee,et al.  The constitution of radicicol , 1964 .

[27]  R. Lett.,et al.  Convergent stereospecific total synthesis of monocillin I and radicicol: some simplifications and improvements , 2002 .

[28]  P. Workman,et al.  Synthesis of resorcinylic macrocycles related to radicicol via ring-closing metathesis , 2006 .

[29]  L. Neckers,et al.  Geldanamycin-induced destabilization of Raf-1 involves the proteasome. , 1997, Biochemical and biophysical research communications.

[30]  P. Workman,et al.  Development of synthetic routes to macrocyclic compounds based on the HSP90 inhibitor radicicol , 2006 .

[31]  Sreenath V. Sharma,et al.  Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol , 1998, Oncogene.

[32]  Xavier Barril,et al.  4-Amino derivatives of the Hsp90 inhibitor CCT018159. , 2006, Bioorganic & medicinal chemistry letters.

[33]  3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. , 2005, Bioorganic & medicinal chemistry letters.

[34]  David A. Fletcher,et al.  The United Kingdom Chemical Database Service , 1996, J. Chem. Inf. Comput. Sci..

[35]  Sreenath V. Sharma,et al.  Development of radicicol analogues. , 2003, Current cancer drug targets.

[36]  M. Drysdale,et al.  Discovery and development of pyrazole-scaffold Hsp90 inhibitors. , 2006, Current topics in medicinal chemistry.

[37]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[38]  M. Lampilas,et al.  Convergent stereospecific total synthesis of monochiral Monocillin I related macrolides , 1992 .

[39]  L. Pearl,et al.  Identification and Structural Characterization of the ATP/ADP-Binding Site in the Hsp90 Molecular Chaperone , 1997, Cell.

[40]  K. Gallo.  Targeting HSP90 to halt neurodegeneration. , 2006, Chemistry & biology.

[41]  P. Workman,et al.  Hsp90 inhibitors in the clinic. , 2006, Handbook of experimental pharmacology.

[42]  L. Pearl,et al.  Crystal structure of an Hsp90–nucleotide–p23/Sba1 closed chaperone complex , 2006, Nature.

[43]  L. Neckers,et al.  KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. , 1999, Cancer research.

[44]  A. Dehner,et al.  NMR Chemical Shift Perturbation Study of the N‐Terminal Domain of Hsp90 upon Binding of ADP, AMP‐PNP, Geldanamycin, and Radicicol , 2003, Chembiochem : a European journal of chemical biology.

[45]  Gabriela Chiosis,et al.  Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. , 2006, Journal of medicinal chemistry.

[46]  L. Neckers,et al.  The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-binding Domain in the Carboxyl Terminus of the Chaperone* , 2000, The Journal of Biological Chemistry.

[47]  Yves L Janin,et al.  Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? , 2005, Journal of medicinal chemistry.

[48]  L. Pearl,et al.  High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. , 2004, Analytical biochemistry.

[49]  P. Workman.  Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. , 2004, Cancer letters.

[50]  X. Barril,et al.  Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[51]  S. Barluenga,et al.  Modular asymmetric synthesis of pochonin C. , 2004, Angewandte Chemie.

[52]  S. Lindquist,et al.  HSP90 and the chaperoning of cancer , 2005, Nature Reviews Cancer.

[53]  Vincent Zoete,et al.  Design, synthesis, and biological evaluation of HSP90 inhibitors based on conformational analysis of radicicol and its analogues. , 2005, Journal of the American Chemical Society.

[54]  N. Rosen,et al.  A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. , 2001, Chemistry & biology.

[55]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[56]  X. Barril,et al.  Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.

[57]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. , 2006, Current topics in medicinal chemistry.

[58]  M. Lampilas,et al.  Convergent stereospecific total synthesis of Monocillin I and Monorden (or Radicicol) , 1992 .

[59]  R. Lett.,et al.  Improvements of the total synthesis of monocillin i and radicicol via Miyaura-Suzuki couplings , 2002 .

[60]  D. Solit,et al.  Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. , 2006, Current opinion in investigational drugs.

[61]  Paul Workman,et al.  The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[62]  K. Zhao,et al.  A simple method of dethioacetalization , 1989 .